| Literature DB >> 30956149 |
Guillaume Garivet1, Walter Hofer1, Antonios Konitsiotis2, Christian Klein2, Nadine Kaiser1, Tom Mejuch3, Eyad Fansa4, Rania Alsaabi5, Alfred Wittinghofer4, Philippe I H Bastiaens6, Herbert Waldmann7.
Abstract
Interference with the signaling activity of the N-myristoylated nonreceptor protein tyrosine kinase Src is considered a viable approach in anti-cancer drug discovery. However, ATP-competitive Src inhibitors have not reached the clinic yet and alternative approaches are in high demand. The UNC119A/B proteins bind the myristoylated N terminus of Src and thereby mediate energy-driven spatial cycles that maintain Src enrichment at the plasma membrane, which is critical for Src signaling activity. We describe the discovery of a potent and specific inhibitor of the UNC119-Src interaction with unprecedented chemotype. The inhibitor binds to UNC119 in cells, and induces redistribution of Src to endomembranes and reduction of activating Src autophosphorylation on Y419. UNC119 inhibition in Src-dependent colorectal cancer cells results in the specific reduction of cell growth and clonogenic potential. Our results demonstrate that small-molecule interference with the dynamics of the Src spatial cycle may provide an opportunity to impair oncogenic Src signaling.Entities:
Keywords: N-myristoylation; Src family kinases; UNC119; inhibitors; protein-protein interactions; target engagement
Year: 2019 PMID: 30956149 DOI: 10.1016/j.chembiol.2019.02.019
Source DB: PubMed Journal: Cell Chem Biol ISSN: 2451-9448 Impact factor: 8.116